Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

摘要

This analysis examined the clinical outcomes of patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in PALOMA-2 who achieved and did not achieve an objective response. Palbociclib plus letrozole provided a significant clinical benefit by prolonging median progression-free survival versus placebo plus letrozole regardless of whether patients achieved an objective response.